Headquarters
11013 OAK KNOLL DR, AUSTIN, TX 78759-4773, US
AUSTIN, TX, US
FAETH THERAPEUTICS, INC
From the company
Faeth Therapeutics is a clinical-stage oncology company pioneering multi-node inhibition of the PAM (PI3K/AKT/mTOR) pathway. Its lead candidate PIKTOR is an all-oral combination designed to inhibit PI3K-alpha, mTORC1, and mTORC2 simultaneously. The company was founded in 2019 and in February 2026 was acquired by Sensei Biotherapeutics, making PIKTOR the combined company's lead program.
Products & services offered
Capabilities 3
Facilities
Send your requirements
Quantities, certifications, and timing.